



CANADIAN
NEUROLOGICAL
SCIENCES
FEDERATION 
FÉDÉRATION
DES SCIENCES
NEUROLOGIQUES
DU CANADA

The journal

Canadian Journal of Neurological Sciences

Volume 37 Number 6 November 2010





Figure A: CT scan demonstrating large-volume SAH with an associated hyperdense crescent at the level of the retina of the right eye, corresponding to an intra-ocular hemorrhage.

Figure B: Fundoscopy in Terson's syndrome demonstrating subhyaloid hemorrhage.



**Taken from the Neuroimaging Highlight
Terson's Syndrome**

*Submitted by:
Francois Paquette, Tim E. Darsaut,
Mikael Sebag, Alain Weill*

Page 861-862

AN INTERNATIONAL JOURNAL PUBLISHED BY THE CANADIAN NEUROLOGICAL SCIENCES FEDERATION

The official Journal of: The Canadian Neurological Society, The Canadian Neurosurgical Society, The Canadian Society of Clinical Neurophysiologists, The Canadian Association of Child Neurology

Beyond whole brain


there's local control



Leksell Gamma Knife® Perfexion™ treats multiple brain metastases in a single session, reducing the damage to healthy tissue that may limit future treatment options, and allowing for concomitant chemotherapy for optimum primary tumor control. Find out how Elekta is creating new possibilities for the most challenging cases at elekta.com/proof.



Leksell Gamma Knife® Perfexion™



Single-session multiple mets

Human care makes the future possible



ELEKTA

EDITORIALS

- 713** The New Era of Consciousness Science - Are We Ready?
Jeanne Teitelbaum, G. Bryan Young
- 714** Brain Injury is a Major Problem in Canada and Annual Incidence is Not Declining
Charles H. Tator
- 716** CCSVI: Hope, Hype or Snake Oil?
Joel Oger, Mona Alkhajawah
- 717** Telectroke: The Management of Acute Ischemic Stroke from a Distance
Frank L. Silver
- 719** Waiting Lists for Lumbar Spine Referrals in Canada: What is the Solution?
Daryl R. Fourney
- 721** "Here, There, Everywhere", or is it Truly Partial Epilepsy?
Manouchehr Javidan
- 723** What is Adequate Surgical Experience for Junior Neurosurgical Residents?
Vivek Mehta

HISTORICAL REVIEW

- 725** Neuropathology in Canada: The First One Hundred Years
Marc R. Del Bigio, N. Barry Rewcastle

REVIEW ARTICLES

- 745** Multiple Sclerosis - A Vascular Etiology?
Bryce Weir
- 758** Observations on the Ethical and Social Aspects of Disorders of Consciousness
Eric Racine, Catherine Rodrigue, James L. Bernat, Richard Riopelle, Sam D. Shemie
- 769** Chronic Daily Headache in Children and Adolescents: A Multi-Faceted Syndrome
Shashi S. Seshia, Shuu-Jiun Wang, Ishaq Abu-Arafeh, Andrew D. Hershey, Vincenzo Guidetti, Paul Winner, Çiçek Wöber-Bingöl

MEDICAL HYPOTHESIS

- 779** Disconnections in Infantile-Onset Saccade Initiation Delay: A Hypothesis
Michael S. Salman, Kristin M. Ikeda

ORIGINAL ARTICLES

- 783** Hospitalizations and Emergency Department Visits for TBI in Ontario
Angela Colantonio, Cristina Saverino, Brandon Zagorski, Bonnie Swaine, John Lewko, Susan Jaglal, Lee Vernich
- 791** Statins May Increase Intracerebral Hemorrhage Volume
Geneviève Ricard, Marie-Pierre Garant, Nathalie Carrier, Nancy Leblanc, Jean-Martin Boulanger
- 797** Endothelial Progenitor Cells in Patients with Acute Cerebrovascular Ischemia
Askar Mohammad, Usman Ghani, Brenda Schwindt, Ashfaq Shuaib
- 803** TGF- β 1 869T/C Polymorphism and Ischemic Stroke: Sex Difference in Chinese
Hong-miao Tao, Guo-zhong Chen, Xiao-dong Lu, Gan-ping Chen, Bei Shao
- 808** Telectroke in Northern Alberta: A Two Year Experience with Remote Hospitals
Khurshid Khan, Ashfaq Shuaib, Tammy Whitaker, Maher Saqqur, Thomas Jeerakathil, Ken Butcher, Patrick Crumley
- 814** Telemedicine and Epilepsy Care - A Canada Wide Survey
S. Nizam Ahmed, Samuel Wiebe, Carly Mann, Arto Ohinmaa
- 819** Audit of EEG Reporting Temporal Abnormalities
Dang Khoa Nguyen, Marie-Eve Girard, Patrick Cossette, Jean-Marc Saint-Hilaire
- 826** Epileptiform Asymetries and Treatment Response in Juvenile Myoclonic Epilepsy
Karine Létourneau, Cécile Cieuta-Walti, Charles Deacon
- 831** TCD Diastolic Velocity Decay and Pulsatility Index Increment in PVS Cases
Jesús Perez-Nellar, Calixto Machado, Claudio E. Scherle, Mauricio Chinchilla
- 837** Conservative Management of Pituitary Macroadenoma Contacting the Optic Apparatus
Won Hyung A. Ryu, Samantha Tam, Brian Rotenberg, Mohamed Ahmed Labib, Donald Lee, David A. Nicolle, Stan Van Uum, Neil Duggal
- 843** Appropriateness of Lumbar Spine Referrals to a Neurosurgical Service
J. Max Findlay, Nathan Deis
- 849** iPhone-Based Teleradiology for the Diagnosis of Acute Cervico-Dorsal Spine Trauma
Jayesh Modi, Pranshu Sharma, Alex Earl, Mark Simpson, J. Ross Mitchell, Mayank Goyal

855 Surgical Activity of First-Year Canadian Neurosurgical Residents

Aria Fallah, Shanil Ebrahim, Faizal Haji, Christopher Gillis, Fady Girgis, Kathryn Howe, George M. Ibrahim, Julia Radic, Mehdi Shahideh, M. Christopher Wallace

NEUROIMAGING HIGHLIGHTS

861 Terson's Syndrome

Francois Paquette, Tim E. Darsaut, Mikael Sebag, Alain Weill

863 Clavicle Pseudarthrosis: A Rare Cause of Thoracic Outlet Syndrome

Kathleen Joy Khu, Rajiv Midha

866 CTA Source Images as a Predictor of Final Infarct Volume are Time-Dependent

Dylan Blacquiere, Miguel Bussière, Cheemun Lum, Dar Dowlatshahi

CRITICALLY APPRAISED TOPIC (CAT)

868 Decompressive Craniectomy in Stroke

A. Al-Khotani, A. Parrent, M.E. Jenkins, J.G. Burneo, and the University of Western Ontario Evidence-Based Neurology Group

BRIEF COMMUNICATIONS

870 Hiccups due to Central Nervous System Disease: Analysis of 71 Inpatients

James R. Keane

873 Pediatric Sinonasal Undifferentiated Carcinoma: Case Report and Literature Review

Jefferson R. Wilson, Shobhan Vachhrajani, Jennifer Li, Melody Sun, Cynthia Hawkins, James T. Rutka

878 Spinal Neurocysticercosis Manifesting as Recurrent Aseptic Meningitis

Mark I. Boulos, Richard I. Aviv, Liesly Lee

881 Cerebral Arteriovenous Malformations Causing Cerebrospinal Fluid Fistula

Olivier X. Beaudoin, Marc Lévesque, Manon Bélair, Issam Saliba, Michel W. Bojanowski

885 Acute Neurogenic Pulmonary Edema After Depth Electrode Placement for Epilepsy Surgery

F.D. Jacob, M.B. Wheatley, D.B. Sinclair

888 An Unusual Case of Retro-Orbital Pain with Diplopia

Michael Paci, Theodore H. Wein, Sabah Bekhor

890 Supranuclear Ophthalmoplegia in Powassan Encephalitis

Pascale Trépanier, Vilayvong Loungarath, Alain Gourdeau, Christiane Claessens, Martin Savard

893 Infantile-Onset Saccade Initiation Delay in a Child with a Thin Intercollicular Commissure

Michael S. Salman, Kristin M. Ikeda, Jens Wrogemann

897 Blindness with Superior Vena Cava Obstruction after Cardiac Surgery

H. Algethamy, D. Nicolle, R. Novick, A. Saito, G.B. Young

901 Post-Surgery Musical Hallucinations of a Patriotic Canadian Song

Camilla L. Wong, Shree Bhalerao

904 Tuberculous Abscess Causing Disruption of the Cranium

G.G. Alvarez, K.B. Sharma, K. Breen, R. Glikstein, H. St. Amand, V. DaSilva

906 Traumatic Coronal Suture Diastasis and Contre-Coup Epidural Hematoma

Mohammed F. Shamji, Howard Lesiuk

REFLECTIONS

909 Navigating an International Research Elective in a Resource-Poor Setting

Jorina Elbers

MEMORIAM

912 Fred Plum (1924-2010)

G.C. Ebers

COMMENTARY

914 Reproduction of Tables: Are Some Publishers Ignoring Fair Use/Dealing?

Shashi S. Seshia

917 Books Received/Books Reviewed

922 Calendar of Events

923 Author Index to Volume 37 - 2010

926 Subject Index to Volume 37 - 2010

A-10 CNSF Sponsors

A-11, A-12 Information for Authors

A-13 Board of Directors/Committee Chairs

A-17 Advertisers Index

A-17, A-18 Classified Ads

The only once-daily treatment for PARKINSON'S DISEASE†

AZILECT®: Efficacy and convenient once-daily dosing

AZILECT® (rasagiline mesylate) is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa.

AZILECT® is contraindicated with meperidine, tramadol, methadone, propoxyphene, dextromethorphan, St. John's wort, cyclobenzaprine, sympathomimetic amines, antidepressants and other MAO inhibitors. Patients taking AZILECT® should not undergo elective surgery requiring general anesthesia. AZILECT® is contraindicated in patients with pheochromocytoma. AZILECT® may cause hallucinations and as adjunct to levodopa there is the possibility of increased dyskinesia and postural hypotension. AZILECT® should not be used at daily doses exceeding the maximum recommended (1 mg/day) because of the risks associated with nonselective inhibition of MAO. Patients taking ciprofloxacin and other CYP1A2 inhibitors should use 0.5 mg daily of AZILECT®.

No significant differences in safety profile were observed based on age or gender. Overall, in phase I/III clinical trials, the long-term safety profile was similar to that observed with shorter duration exposure.

The most commonly observed adverse events that occurred in $\geq 5\%$ of patients and were at least 1.5 times the incidence in the placebo group were flu syndrome (5%, 1%), arthralgia (7%, 4%), depression (5%, 2%), dyspepsia (7%, 4%) and falls (5%, 3%) in patients receiving AZILECT® 1 mg as monotherapy; and dyskinesia (18%, 10%), accidental injury (12%, 5%), weight loss (9%, 3%), postural hypotension (9%, 3%), vomiting (7%, 1%), anorexia (5%, 1%), arthralgia (8%, 4%), abdominal pain (5%, 1%), nausea (12%, 8%), constipation (9%, 5%), dry mouth (6%, 3%), rash (6%, 3%), ecchymosis (5%, 3%), somnolence (6%, 4%) and paresthesia (5%, 3%) for AZILECT® 1 mg as adjunct therapy.

† Comparative clinical significance unknown.

TEVA
TEVA CANADA INNOVATION

AZILECT® is a registered trademark of Teva Pharmaceutical Industries Ltd. and is used under licence.
TEVA and the design version thereof are registered trademarks of Teva Pharmaceutical Industries Ltd. and are used under licence.
©2010 Teva Canada Innovation G.P. – S.E.N.C.
Montreal, Quebec H3A 3L4

Once-Daily
AZILECT
(rasagiline tablets)



Editor-in-Chief/Rédacteur en chef

G. Bryan Young LONDON, ON

Associate Editors/Rédacteurs associés

J. Max Findlay EDMONTON, AB
Michael Shevell MONTREAL, QC
Timothy J. Benstead HALIFAX, NS
Mike Poulter LONDON, ON
Serge Gauthier VERDUN, QC
Robert Hammond LONDON, ON

Past Editors/Anciens rédacteurs en chef

Douglas W. Zochodne CALGARY, AB
James A. Sharpe TORONTO, ON
Robert G. Lee CALGARY, AB
Robert T. Ross WINNIPEG, MB
(Emeritus Editor, Founding Editor)

Editorial Board/Conseil d'édition

Jorge Burneo LONDON, ON
Richard Desbiens QUEBEC CITY, QC
David Fortin SHERBROOKE, QC
Mark Hamilton CALGARY, AB
Hans-Peter Hartung DUSSELDORF, GERMANY
Michael Hill CALGARY, AB
Alan C. Jackson WINNIPEG, MB
Daniel Keene OTTAWA, ON
Terence Myles CALGARY, AB
James Perry TORONTO, ON
Oksana Suchowersky CALGARY, AB
Brian Toyota VANCOUVER, BC
Brian Weinshenker ROCHESTER, MN, USA
Samuel Wiebe CALGARY, AB
Elaine Wirrell ROCHESTER, MN, USA

SECTION EDITORS/CONSEIL DE RÉDACTION

Neuroimaging Highlight/Neuroimagerie

Richard Farb TORONTO, ON
David Pelz LONDON, ON

Neuropathological Conference/Conférence sur la neuropathologie

Robert Hammond LONDON, ON

**Book Review/Critiques de livres
Reflections/Reflets**

Andrew Kirk SASKATOON, SK

**Critically Appraised Topic Summaries
(CATS)**

Jorge Burneo LONDON, ON
Mary Jenkins LONDON, ON

**Editorial Review Board/Conseil de
Revue d'édition**

Donald Brunet KINGSTON, ON
Lionel Carmant MONTREAL, QC
Colin Chalk MONTREAL, QC
K. Ming Chan EDMONTON, AB
Robert Chen TORONTO, ON
Mary Connolly VANCOUVER, BC
Joseph Dooley HALIFAX, NS
Paolo Federico CALGARY, AB
Daryl Fourney SASKATOON, SK
Hannah Glass SAN FRANCISCO, CA, USA
Alan Goodridge ST. JOHN'S, NL
Ian Grant HALIFAX, NS
Alan Guberman OTTAWA, ON
John Hurlbert CALGARY, AB
Manouchehr Javidan VANCOUVER, BC
Patrick McDonald WINNIPEG, MB
Martin McKeown VANCOUVER, BC
Joseph Megyesi LONDON, ON
Vivek Mehta EDMONTON, AB
Steven Miller VANCOUVER, BC
Neelan Pillay CALGARY, AB
Christopher Power EDMONTON, AB
Alex Rajput SASKATOON, SK
Jean Raymond MONTREAL, QC
Gary Redekop VANCOUVER, BC
Mark Sadler HALIFAX, NS
Harvey Sarnat CALGARY, AB
John Stewart VANCOUVER, BC
Jeanne Teitelbaum MONTREAL, QC
Eve Tsai OTTAWA, ON
Shannon Venance LONDON, ON
Matt Wheatley EDMONTON, AB
Jerome Yager EDMONTON, AB

Journal Staff - Calgary, AB

Dan Morin, *Chief Executive Officer*
Maggie McCallion, *Designer/*
Production Coordinator
Cindy Leschyshyn, *Editorial Coordinator*

**Advertising representative/Représentant de
publicité:**

Brett Windle
Corporate Development Coordinator
Tel (403) 229-9575 Fax (403) 229-1661
E-mail: brett-windle@cnsfederation.org

Printer/Imprimeur:

Unicom Graphics, 4501 Manitoba Road SE
Calgary, Alberta T2G 4B9

The official journal of: / La Revue officielle de:

**The Canadian Neurological Society
La Société Canadienne de Neurologie**

**The Canadian Neurosurgical Society
La Société Canadienne de Neurochirurgie**

**The Canadian Society of Clinical Neurophysiologists
La Société Canadienne de Neurophysiologie Clinique**

**The Canadian Association of Child Neurology
L'Association Canadienne de Neurologie Pédiatrique**

The permanent secretariat for the four societies and the Canadian Neurological Sciences Federation is at:
Le secrétariat des quatre associations et du Fédération des sciences neurologiques du Canada est situé en permanence à:

7015 Macleod Trail SW, Suite 709
Calgary, Alberta, Canada T2H 2K6

The Canadian Journal of Neurological Sciences is published bi-monthly. The annual subscription rate for Individuals are: C\$120 (Canada), C\$140 (Foreign including USA). Subscription rates for Institutions are: C\$150 (Canada), C\$170 (Foreign including USA). See www.cjns.org for details. Single copies C\$30 each plus postage and handling. Communications should be sent to: Canadian Journal of Neurological Sciences, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Telephone (403) 229-9575; Fax (403) 229-1661. E-mail: journal@cjns.org; Web: www.cjns.org
COPYRIGHT© 2010 by THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. All rights reserved. No part of this journal may be reproduced in any form without the prior permission of The Canadian Journal of Neurological Sciences. Postage paid at Calgary, Alberta.

Le Journal Canadien des Sciences Neurologiques est publié 6 fois par an. L'abonnement annuel est de 120 \$C (non-membres au Canada); 140 \$C (Etats Unis et ailleurs); l'abonnement annuel pour les institutions est de 150 \$C (non-membres au Canada); 170 \$C (Etats Unis et ailleurs); Voir www.cjns.org pour détails. Copie simple: 30 \$C plus affranchissement et manutention. Toutes les communications doivent être adressés à Journal Canadien des Sciences Neurologiques, 709 - 7015 Macleod Trail SW, Calgary, AB Canada T2H 2K6. Téléphone (403) 229-9575; Fax (403) 229-1661. E-mail journal@cjns.org; Web: www.cjns.org. DROITS D'AUTEUR© 2010: THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES INC. Tous droits réservés. Aucune partie de ce Journal ne peut être reproduite, sous quelque forme que ce soit, sans la l'autorisation du Journal Canadien des Sciences Neurologiques. Port payé à Calgary, Alberta.

This journal is indexed by / Cette Journal est cité et indexé dans: AgBio, BIOBASE, BioLab, BIOSIS Prev, CABS, ChemAb, CSA, CurAb, CurCont, E-psyche, EBSCO, Elsevier, EMBASE, ExcerptMed, IBZ, Index Medicus, Index to Dental Literature, Index to Scientific Reviews, Inpharma, Internationale Bibliographie der Rezensionen Geistes- und Sozialwissenschaftlicher Literatur, JW-N, MEDLINE, MetaPress, MycolAb, NRN, NSCI, PE&ON, Personal Alert, PsycFIRST, PsycInfo, Psychological Abstracts, PubMed, Reac, RefZh, SCI, SCOPUS, Swets, TOCpre, Web of Science
ADVERTISING.

ISSN 0317 - 1671





Wider Scope, Same Commitment.

Building on our proven success in commercialising innovative neurological products, we, at Teva Canada Innovation, are now **extending our expertise to other therapeutic areas.**

As one of the **20 principal pharmaceutical companies in the world**, our goal is to see more patients benefit from our innovative, creative and **distinctly human approach to healing through pharmaceuticals.**

TEVA CANADA INNOVATION

A division of Teva Pharmaceutical Industries Ltd., **Teva Canada Innovation** develops and markets innovative products in Canada such as Copaxone[®], Azilect[®] and Frova[®]. Another Canadian division of Teva Pharmaceutical Industries Ltd., **Teva Canada Limited** is responsible for the generic products sector in Canada.



Our pursuit. Life's potential.®

Allergan is a proud supporter of the CNSF e-CPD Project

Allergan is a multi-specialty health care company established 60 years ago with a commitment to uncover the best of science and develop and deliver innovative and meaningful treatments to help people reach their life's potential. Today, we have more than 8,000 highly dedicated and talented employees, global marketing and sales capabilities with a presence in more than 100 countries, a rich and ever-evolving portfolio of pharmaceuticals, biologics and medical devices, and state-of-the-art resources in R&D, manufacturing and safety surveillance that help millions of patients see more clearly, move more freely and express themselves more fully. From our beginnings as an eye care company to our focus today on several medical specialties, including ophthalmology, neurosciences, obesity, urologics, medical aesthetics and dermatology, Allergan is proud to celebrate 60 years of medical advances and proud to support the patients and physicians who rely on our products and the employees and communities in which we live and work. In Canada, Allergan employs more than 170 people and has a corporate head office in Markham, Ontario.

Choose NE migraine therapy that has demonstrated rapid, reliable relief.

1-4†§

- Demonstrated headache response as quickly as 30 minutes postdose vs. placebo (RELPA 40 mg: 9%; placebo: 4%, $p<0.05$)^{1,2†}
- Provided greater relief of associated symptoms vs. sumatriptan 100 mg at 2 hours (absence of nausea: 74% vs. 67%, $p<0.01$; absence of photophobia: 71% vs. 63%, $p<0.01$; absence of phonophobia: 74% vs. 67%, $p<0.01$)^{3†}
- Demonstrated superior functional response at 2 hours vs. sumatriptan 100 mg (68% vs. 61%, $p<0.01$; 63% vs. 46%, $p<0.005$)^{3,4†§}



RELPA is indicated for the acute treatment of migraine with or without aura in adults. RELPA tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, ophthalmoplegic or basilar migraine. Safety and effectiveness of RELPA tablets have not been established for cluster headache, which is present in an older, predominantly male population. Among 5984 patients who treated a single migraine headache with RELPA 20 mg, 40 mg or 80 mg tablets in short-term, placebo-controlled trials, the most common and dose-related adverse events reported with treatment with RELPA were asthenia (7.2%), nausea (7.8%), dizziness (5.7%) and somnolence (5.2%). RELPA 80 mg is not an available dose. The maximum daily dose is 40 mg.

RELPA is contraindicated in patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes, valvular heart disease or cardiac arrhythmias (especially tachycardias). In addition, patients with other significant underlying cardiovascular diseases (e.g., atherosclerotic disease, congenital heart disease) or uncontrolled or severe hypertension should not receive RELPA. Ischemic cardiac syndromes include, but are not restricted to, angina pectoris of any type (e.g., stable angina of effort and vasospastic forms of angina such as Prinzmetal's variant), all forms of myocardial infarction, and silent myocardial ischemia. Cerebrovascular syndromes include, but are not limited to, strokes of any type as well as transient ischemic attacks (TIAs). Peripheral vascular disease includes, but is not limited to, ischemic bowel disease, or Raynaud's syndrome. Because RELPA may increase blood pressure it is contraindicated in patients with uncontrolled or severe hypertension. RELPA is contraindicated within 72 hours of treatment with potent CYP3A4 inhibitors (i.e., ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir). RELPA is contraindicated within 72 hours with drugs that have demonstrated potent CYP3A4 inhibition and have this potent effect described in the CONTRAINDICATIONS, or WARNINGS AND PRECAUTIONS sections of their labelling. RELPA is contraindicated within 24 hours of treatment with another 5-HT₁ agonist, an ergotamine-containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide. RELPA is contraindicated in patients with hemiplegic, ophthalmoplegic or basilar migraine, patients with severe hepatic impairment, and those with known hypersensitivity to eletriptan or to any of its inactive ingredients.

† In a multicentre, double-blind, placebo-controlled, parallel-group clinical trial, 1334 outpatients with a diagnosis of migraine were randomized to receive RELPA 20 mg, 40 mg, or 80 mg, or placebo for the treatment of up to 3 migraine attacks. The efficacy, consistency, tolerability and safety of RELPA were evaluated.

‡ In a randomized, double-blind, double-dummy, parallel-group study conducted in 2113 patients with a diagnosis of migraine. Subjects were randomized to receive RELPA 40 mg, sumatriptan 100 mg or placebo for the treatment of a single migraine attack.

§ In a randomized, double-blind, double-dummy, placebo-controlled study conducted in 1008 patients with a history of migraine. Subjects were randomized to receive RELPA 40 mg or 80 mg, sumatriptan 50 mg or 100 mg, or placebo to treat up to 3 migraine attacks.

For complete prescribing information, please refer to the Product Monograph. The Product Monograph is available upon request.

Member



™ Pfizer Inc., used under license

RELPA® Pfizer Products Inc., owner/Pfizer Canada Inc., licensee



© 2010 Pfizer Canada Inc., Kirkland, Quebec H9J 2M5



Working together for a healthier world™

RELPA[®]
eletriptan HBr 40 mg



*Fictitious patient. May not be representative of all fibromyalgia cases.



FACED WITH PAIN*

IN HER STRUGGLE WITH FIBROMYALGIA

First treatment indicated in Canada for adults for the management of pain associated with

fibromyalgia¹

Pregabalin: first-line treatment for chronic

neuropathic pain²

DEMONSTRATED SIGNIFICANT RELIEF IN PAIN AND PAIN-RELATED SLEEP DIFFICULTIES IN FIBROMYALGIA¹

Demonstrated powerful, rapid and sustained pain relief^{1,3-5}

In fibromyalgia:

- In a 14 week study, LYRICA demonstrated significant pain reduction as early as week 1 ($p < 0.05$ for all doses). Mean changes in pain scores at the end of the study for LYRICA-treated patients were significantly greater versus placebo (300 mg/day, $n=183$: -1.75, $p=0.0009$; 450 mg/day, $n=190$: -2.03, $p < 0.0001$; 600 mg/day, $n=188$: -2.05, $p < 0.0001$; placebo, $n=184$: -1.04)³
- In another study of 26 weeks' duration of patients who initially responded to LYRICA during a 6-week, open-label phase, 68% of those who continued on their optimized dose ($n=279$) maintained a treatment response versus 39% of those on placebo ($n=287$). The time to loss of therapeutic response was longer in the LYRICA group ($p < 0.0001$)⁴

Also in neuropathic pain (NeP):

- Sustained pain relief (starting at week 2 for LYRICA 150-600 mg/day, $n=141$; $p < 0.05$ vs placebo, $n=65$) was demonstrated throughout a 12 week study in patients with DPN or PHN⁵

Demonstrated effective in relieving pain-related sleep difficulties^{1,6}

In fibromyalgia:

- In a 13 week study, LYRICA reduced overall MOS-Sleep Scale scores significantly more at the end of the study vs. placebo (300 mg/day -19.1, $p=0.0174$; 450 mg/day: -20.41, $p=0.0026$; 600 mg/day: -19.49, $p=0.0101$; placebo: -14.29)⁶

Also in NeP:

- LYRICA reduced sleep disturbances across several studies in DPN and PHN, of 8-12 weeks duration¹

Flexible dosing across all indications^{1†}

LYRICA (pregabalin) is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN), postherpetic neuralgia (PHN) and spinal cord injury in adults. LYRICA may be useful in the management of central neuropathic pain in adults. LYRICA is indicated for the management of pain associated with fibromyalgia in adults. The efficacy of LYRICA in the management of pain associated with fibromyalgia for up to 6 months was demonstrated in a placebo-controlled trial in patients who had initially responded to LYRICA during a 6-week open-label phase.

LYRICA is contraindicated in patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container.

The most commonly observed adverse events ($\geq 5\%$ and twice the rate as that seen with placebo) in the recommended dose range of 150 mg/day to 600 mg/day in PHN and DPN patients were: dizziness (9.0-37.0%), somnolence (6.1-24.7%), peripheral edema (6.1-16.2%), and dry mouth (1.9-14.9%) and were dose related; in spinal cord injury patients: somnolence (41.4%), dizziness (24.3%), asthenia (15.7%), dry mouth (15.7%), edema (12.9%), constipation (12.9%), amnesia (10.0%), myasthenia (8.6%), amblyopia (8.6%), and thinking abnormal (8.6%); in fibromyalgia patients: dizziness (37.5%), somnolence (18.6%), weight gain (10.6%), dry mouth (7.9%), blurred vision (6.7%), and peripheral edema (6.1%). In LYRICA-treated fibromyalgia patients, the most commonly observed dose-related adverse events were: dizziness (22.7-46.5%), somnolence (12.9-20.7%), weight gain (7.6-13.7%), peripheral edema (5.3-10.8%). The most commonly observed adverse events in the PHN, DPN, spinal cord injury and fibromyalgia patients were usually mild to moderate in intensity. Discontinuation rates due to adverse events for LYRICA and placebo, respectively, were 9% and 4% in DPN, 14% and 7% in PHN, 21% and 13% in spinal cord injury, and 20% and 11% in fibromyalgia. There was a dose-dependent increase in rate of discontinuation due to adverse events in fibromyalgia.

There have been post-marketing reports of angioedema in patients, some without reported previous history/episodes, including life-threatening angioedema with respiratory compromise. Caution should be exercised in patients with previous history/episodes of angioedema and in patients who are taking other drugs associated with angioedema.

In clinical trials and in post-marketing experience, there have been reports of patients, with or without previous history, experiencing renal failure alone or in combination with other medications. Caution is advised when prescribing to the elderly or those with any degree of renal impairment.

There have been post-marketing reports of events related to reduced lower gastrointestinal tract function (e.g., intestinal obstruction, paralytic ileus, and constipation) in patients, some without reported previous history/episode(s), during initial/acute and chronic treatment with LYRICA, primarily in combination with other medications that have the potential to produce constipation. Some of these events were considered serious and required hospitalization. In a number of instances, patients were taking opioid analgesics including tramadol. Caution should be exercised when LYRICA and opioid analgesics are used in combination, and measures to prevent constipation may be considered, especially in female patients and elderly as they may be at increased risk of experiencing lower gastrointestinal-related events.

Dosage reduction is required in patients with renal impairment (creatinine clearance < 60 mL/min) and in some elderly patients as LYRICA is primarily eliminated by renal excretion.

Please see Prescribing Information for complete Warnings and Precautions, Adverse Reactions, Dosage and Administration and patient selection criteria.

† Please consult Prescribing Information for complete Dosage and Administration instructions.



Working together for a healthier world™

©2010
Pfizer Canada Inc.
Kirkland, Quebec
H9J 2M5

™Pfizer Inc, used under license
LYRICA® C.P. Pharmaceuticals International C.V.,
owner/Pfizer Canada Inc., Licensee



2010 SPONSORS

The Canadian Neurological Sciences Federation is pleased to recognize those Sponsors who supported the 2010 Congress. These organizations partner with CNSF to determine the causes of, and develop treatment for diseases and injuries of the nervous system, and in the care of patients with these diseases and injuries. Along with support of the Canadian Journal of Neurological Sciences and other initiatives the CNSF maintains throughout the year, these organizations graciously provided educational grants to the Annual Congress, this year in Quebec City, Quebec, June 8-11, 2010.

PLATINUM



MERCK

Merck Frosst Canada Ltd., Kirkland, Quebec



THE EPILEPSY COMPANY™

GOLD



**Boehringer
Ingelheim**



TEVA CANADA INNOVATION
E-CPD CO-FOUNDING SPONSOR



ALLERGAN

Our pursuit. Life's potential.®
E-CPD CO-FOUNDING SPONSOR

SILVER



Scotiabank®



We Innovate Healthcare

Talecris
BIOTHERAPEUTICS

BRONZE



**Neurological Sciences Foundation
of Canada (NSFC)**



ELEKTA

Codman
a Johnson-Johnson company

**NSFC - CNS - Don Paty
Fund**

SUPPORTERS

**Synthes Canada
Medtronic of Canada**

**Actelion Pharmaceuticals
Canada Microsurgical**